Immutep Limited (PRRUF)
USD 0.2
(-26.74%)
USD 0.2
(-26.74%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -160.82 Million AUD | -31.1% |
| 2023 | -122.18 Million AUD | -56.13% |
| 2022 | -78.26 Million AUD | -36.55% |
| 2021 | -57.31 Million AUD | -231.85% |
| 2020 | -17.27 Million AUD | -93.5% |
| 2019 | -8.92 Million AUD | 46.97% |
| 2018 | -16.82 Million AUD | -160.6% |
| 2017 | -6.45 Million AUD | 59.26% |
| 2016 | -15.85 Million AUD | -201.88% |
| 2015 | -5.25 Million AUD | 63.02% |
| 2014 | -14.2 Million AUD | 35.52% |
| 2013 | -22.02 Million AUD | -29.51% |
| 2012 | -17 Million AUD | 62.98% |
| 2011 | -45.93 Million AUD | -207.42% |
| 2010 | -14.94 Million AUD | -2003.79% |
| 2009 | -710.17 Thousand AUD | 35.98% |
| 2008 | -1.1 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -160.19 Million AUD | -31.1% |
| 2024 Q2 | -102.12 Million AUD | 0.0% |
| 2024 Q4 | -160.82 Million AUD | 0.0% |
| 2023 Q2 | -67.42 Million AUD | 0.0% |
| 2023 Q4 | -122.18 Million AUD | 0.0% |
| 2023 FY | -122.18 Million AUD | -56.13% |
| 2022 FY | -78.26 Million AUD | -36.55% |
| 2022 Q4 | -78.26 Million AUD | 0.0% |
| 2022 Q2 | -96.61 Million AUD | 0.0% |
| 2021 Q2 | -45.12 Million AUD | 0.0% |
| 2021 FY | -57.31 Million AUD | -231.85% |
| 2021 Q4 | -57.31 Million AUD | 0.0% |
| 2020 Q4 | -17.27 Million AUD | 0.0% |
| 2020 FY | -17.27 Million AUD | -93.5% |
| 2020 Q2 | -12.03 Million AUD | 0.0% |
| 2019 FY | -8.92 Million AUD | 46.97% |
| 2019 Q4 | -8.92 Million AUD | 0.0% |
| 2019 Q2 | -18.85 Million AUD | 0.0% |
| 2018 Q4 | -16.82 Million AUD | 0.0% |
| 2018 Q2 | -7.49 Million AUD | 0.0% |
| 2018 FY | -16.82 Million AUD | -160.6% |
| 2017 Q4 | -6.45 Million AUD | 22.09% |
| 2017 Q3 | -8.28 Million AUD | 25.78% |
| 2017 Q2 | -11.16 Million AUD | 0.0% |
| 2017 FY | -6.45 Million AUD | 59.26% |
| 2016 Q2 | -20.78 Million AUD | 0.0% |
| 2016 FY | -15.85 Million AUD | -201.88% |
| 2016 Q4 | -15.85 Million AUD | 0.0% |
| 2015 FY | -5.25 Million AUD | 63.02% |
| 2015 Q4 | -5.25 Million AUD | 0.0% |
| 2015 Q2 | -5.06 Million AUD | 0.0% |
| 2014 FY | -14.2 Million AUD | 35.52% |
| 2014 Q4 | -14.2 Million AUD | 0.0% |
| 2014 Q2 | -17.26 Million AUD | 0.0% |
| 2013 Q4 | -22.02 Million AUD | 0.0% |
| 2013 FY | -22.02 Million AUD | -29.51% |
| 2013 Q2 | -11.02 Million AUD | 0.0% |
| 2012 FY | -17 Million AUD | 62.98% |
| 2012 Q4 | -17 Million AUD | 0.0% |
| 2011 FY | -45.93 Million AUD | -207.42% |
| 2010 FY | -14.94 Million AUD | -2003.79% |
| 2009 FY | -710.17 Thousand AUD | 35.98% |
| 2008 FY | -1.1 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -23794.223% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 13349.112% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 16059.793% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 475.831% |
| GB Sciences, Inc. | 1.74 Million USD | 9304.367% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -1719.355% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1735155.547% |
| Skye Bioscience, Inc. | -5.72 Million USD | -2711.02% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1598166.216% |
| Agentix Corp. | 37.63 Thousand USD | 427485.358% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 2947.359% |
| Biomind Labs Inc. | 711.4 Thousand USD | 22707.384% |
| ContraFect Corporation | -6.02 Million USD | -2568.924% |
| CSL Limited | 10.52 Billion USD | 101.528% |
| CytoDyn Inc. | 20.26 Million USD | 893.749% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 44810.846% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 25941.691% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 470.285% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -787970.286% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 17445.968% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 25420.803% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -2451.015% |
| SQZ Biotechnologies Company | -36.23 Million USD | -343.814% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 18795.852% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 1120.297% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 7272.733% |
| Mesoblast Limited | 55.85 Million USD | 387.924% |
| Marizyme, Inc. | 18.56 Million USD | 966.116% |
| Genus plc | 190.6 Million USD | 184.381% |
| Pharming Group N.V. | 109.8 Million USD | 246.47% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 23751.38% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 14019.452% |
| IMV Inc. | 7.67 Million USD | 2196.72% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 3023.163% |
| MultiCell Technologies, Inc. | 90.04 USD | 178620028.92% |
| ONE Bio Corp. | 9.04 Million USD | 1879.079% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1342.309% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 626.378% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 8143.915% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 1355.833% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 115139.186% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 809630.296% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -87408.098% |
| Enzolytics Inc. | 981.65 Thousand USD | 16483.477% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 92.073% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -242.103% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 2374.502% |
| Genscript Biotech Corporation | -1.06 Billion USD | 84.847% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 4005.499% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 40122.343% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 6840.448% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 97863.274% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -877885.501% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 7293.268% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 119552.301% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -21812.017% |
| Helix BioMedix, Inc. | -2.57 Million USD | -6157.875% |
| EV Biologics, Inc. | 1.36 Million USD | 11856.783% |
| Q BioMed Inc. | 4.06 Million USD | 4061.307% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 893.201% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 365.633% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 3696.355% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 7403.85% |
| HST Global, Inc. | 96.79 Thousand USD | 166258.073% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -12276952.214% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 78090.362% |
| Halberd Corporation | 144.72 Thousand USD | 111230.647% |
| Resverlogix Corp. | 6.45 Million USD | 2593.092% |
| Cell Source, Inc. | 9.23 Million USD | 1842.092% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 6037.698% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -2624.441% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 80341.371% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 7482.693% |
| Kadimastem Ltd | -253.1 Thousand USD | -63443.308% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 118366.466% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 80013.634% |
| LadRx Corporation | -2.03 Million USD | -7797.463% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 25420.803% |
| Affymax, Inc. | -5.59 Million USD | -2773.493% |
| Itoco Inc. | 228.3 Thousand USD | 70544.968% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 3344.49% |
| Mobile Lads Corp. | 484.23 Thousand USD | 33313.291% |
| International Stem Cell Corporation | 2.59 Million USD | 6309.629% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 8569.545% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -24857610.046% |
| Qrons Inc. | 351.42 Thousand USD | 45864.664% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2187.066% |
| SYBLEU INC | 473.71 Thousand USD | 34050.735% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -64329.687% |
| Rebus Holdings, Inc. | 305 Thousand USD | 52830.946% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 3708.449% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 257785.713% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 7474.45% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 4783.442% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 1980.386% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 20916.454% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -12766.351% |
| Neutra Corp. | 52.18 Thousand USD | 308279.018% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -6361.606% |
| PureTech Health plc | -167.19 Million USD | 3.808% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -65569.306% |
| IXICO plc | -4.44 Million USD | -3518.545% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 1316.653% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 393.211% |
| CSL Limited | 10.52 Billion USD | 101.528% |
| Cellectis S.A. | -43.81 Million USD | -267.032% |